Compare · ARGX vs DNA
ARGX vs DNA
Side-by-side comparison of argenx SE (ARGX) and Ginkgo Bioworks Holdings Inc. (DNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and DNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.32B, about 108.3x DNA ($510.8M).
- Over the past year, ARGX is up 51.1% and DNA is up 3.4% - ARGX leads by 47.7 points.
- ARGX has been more active in the news (5 items in the past 4 weeks vs 2 for DNA).
- ARGX has more recent analyst coverage (25 ratings vs 17 for DNA).
- Company
- argenx SE
- Ginkgo Bioworks Holdings Inc.
- Price
- $881.05-1.21%
- $8.11-1.10%
- Market cap
- $55.32B
- $510.8M
- 1M return
- +12.01%
- -21.79%
- 1Y return
- +51.10%
- +3.38%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- 2021
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 17
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest DNA
- Officer Coen Steven P. converted options into 743 shares and sold $2,559 worth of shares (307 units at $8.33), increasing direct ownership by 0.87% to 50,704 units (SEC Form 4) (tax liability)
- Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
- Amendment: SEC Form SCHEDULE 13G/A filed by Ginkgo Bioworks Holdings Inc.
- The $59B Quiet Shift Reshaping How Patients Access Care
- SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
- Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
- SEC Form DEFA14A filed by Ginkgo Bioworks Holdings Inc.
- SEC Form DEF 14A filed by Ginkgo Bioworks Holdings Inc.